# Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

> **NCT03753087** · PHASE4 · COMPLETED · sponsor: **National Medical Research Center for Cardiology, Ministry of Health of Russian Federation** · enrollment: 70 (actual)

## Conditions studied

- Heart Failure, Diastolic
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Empagliflozin
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT03753087
- **Lead sponsor:** National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-01-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03753087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03753087, "Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03753087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*